Company intelligence / Profile preview

Prostacare

Sydney, New South Wales, Australiaprostacare.com ↗

Ownership: Private
Development stage: Other

Overview

Prostacare’s Neuflo® System has completed pre-clinical studies and a clinical feasibility trial demonstrating it as a simple, cost-effective, nearly painless office-based procedure for treating enlarged prostates (BPH), with quick symptomatic relief and minimal side effects. The company plans to seek CE Mark approval in Europe before expanding to other markets including the USA. Earlier development also explored DC Ablation for prostate cancer with promising control and safety profile; further trials are anticipated.

Therapeutic areas: Men's HealthOncology
Modalities: Device (Neuflo® System)Device-based ablation therapy (Potential future for DC Ablation)
Industry: Therapeutic Medical Devices

Partnerships

Seleon GmbH (Germany)Ionix Medical

Beyond the preview

Go deeper on Prostacare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostacare.

Explore the full profile